Premium
Metformin Causes a Reduction in Basal and Post‐venous Occlusion Plasminogen Activator Inhibitor‐1 in Type 2 Diabetic Patients
Author(s) -
Grant P. J.,
Stickland M. H.,
Booth N. A.,
Prentice C. R. M.
Publication year - 1991
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1991.tb01610.x
Subject(s) - medicine , metformin , plasminogen activator , placebo , basal (medicine) , fibrinolysis , diabetes mellitus , occlusion , endocrinology , gastroenterology , pathology , alternative medicine
The effects of metformin on the fibrinolytic system were studied pre‐ and post‐venous occlusion in 38 Type 2 diabetic patients in a double‐blind, placebo‐controlled trial. After a 3‐week run‐in period, 21 patients received metformin and 17 placebo, for 6 weeks. In the metformin‐treated patients basal plasminogen activator inhibitor‐1 antigen (PAI‐1Ag) fell from 57.4 μg l −1 before treatment to 36.1 ( p < 0.05) and 41.0 μg l −1 ( p < 0.01) after 3 and 6 weeks therapy. In this group post‐venous occlusion PAI‐1Ag also fell after 3 weeks ( p < 0.002) and 6 weeks ( p < 0.05) treatment. There were no changes in either basal or post‐venous occlusion concentrations of PAI‐1Ag in the placebo treated group. The fall in PAI‐1Ag was not associated with an increase in basal plasminogen activator activity (PAA) which remained unchanged in both groups. Post‐venous occlusion values for PAA in the metformin treated patients were increased at 3 weeks ( p < 0.05) although there was no difference at 6 weeks.